ClinicalTrials.gov
ClinicalTrials.gov Menu

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00225303
Recruitment Status : Completed
First Posted : September 23, 2005
Last Update Posted : May 19, 2011
Sponsor:
Information provided by:
Tibotec Pharmaceuticals, Ireland